Please enable JavaScript to continue using this application.

Compare $CCCC vs $XFOR | Chartloom

Compare

$CCCC vs $XFOR

C4 Therapeutics, Inc · X4 Pharmaceuticals Inc

CCCC

C4 Therapeutics, Inc

XFOR

X4 Pharmaceuticals Inc

Compare $CCCC vs $XFOR

Comparing C4 Therapeutics, Inc and X4 Pharmaceuticals Inc

CCCCC4 Therapeutics, Inc

XFORX4 Pharmaceuticals Inc

CCCCC4 Therapeutics, Inc

Market cap

$349M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.01x

Rev growth (TTM)

2.3%

YTD performance

63.7%

52W performance

41.7%

FCF yield

-24.4%

XFORX4 Pharmaceuticals Inc

Market cap

$274M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.09x

Rev growth (TTM)

-51.6%

YTD performance

-25.2%

52W performance

-12.3%

FCF yield

-32.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CCCC

XFOR

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

CCCC$349M

XFOR$274M

Enterprise Value

CCCC$271M

XFOR$156M

Price

CCCC$3.16

XFOR$2.91

P/E Ratio

CCCCN/A

XFORN/A

P/S Ratio

CCCC9.97x

XFOR17.32x

EV/Sales

CCCC7.73x

XFOR9.85x

EV/EBITDA

CCCC0.00x

XFOR0.00x

P/B Ratio

CCCC1.47x

XFOR1.81x

P/FCF Ratio

CCCCN/A

XFORN/A

EV/FCF

CCCC-3.17x

XFOR-1.76x

PEG Ratio

CCCCN/A

XFORN/A

Forward P/E (NTM)

CCCCN/A

XFORN/A

Forward P/S (NTM)

CCCC15.01x

XFOR28.09x

Revenue (TTM)

CCCC$35M

XFOR$16M

Revenue Growth (YoY)

CCCC2.3%

XFOR-51.6%

Forward Rev Growth

CCCC-15.9%

XFOR-27.7%

Gross Margin (TTM)

CCCC0.0%

XFOR81.5%

Operating Margin (TTM)

CCCC0.0%

XFOR0.0%

EBITDA Margin (TTM)

CCCC-283.8%

XFOR-544.2%

Net Margin (TTM)

CCCC-289.4%

XFOR-568.8%

FCF Margin (TTM)

CCCC-243.7%

XFOR-560.0%

Net Income (TTM)

CCCC$-101M

XFOR$-90M

FCF (TTM)

CCCC$-85M

XFOR$-89M

EPS (TTM)

CCCC-$0.78

XFOR-$0.71

ROE (TTM)

CCCC-4545.0%

XFOR-6305.0%

ROA (TTM)

CCCC-3090.0%

XFOR-3689.0%

ROIC (TTM)

CCCC-4545.0%

XFOR-4109.0%

Cash

CCCC$79M

XFOR$195M

Debt

CCCC$0

XFOR$77M

Net Cash/Debt

CCCC$79M

XFOR$118M

Current Ratio (TTM)

CCCC5.45x

XFOR11.30x

Quick Ratio (TTM)

CCCC5.29x

XFOR10.87x

Debt/Equity (TTM)

CCCC0.00x

XFOR0.49x

Debt/Assets (TTM)

CCCC0.0%

XFOR0.0%

Interest Coverage (TTM)

CCCCN/A

XFORN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

XFOR0.00x

Beta

CCCC3.16

XFOR0.50

52W Performance

CCCC41.7%

XFOR-12.3%

YTD Performance

CCCC63.7%

XFOR-25.2%

% from 52W High

CCCC-38.9%

XFOR-39.8%

% from 52W Low

CCCC87.0%

XFOR7.8%

Asset Turnover (TTM)

CCCC0.11x

XFOR0.06x

FCF Yield (TTM)

CCCC-24.4%

XFOR-32.3%

Earnings Yield (TTM)

CCCC-29.0%

XFOR-32.8%

Dividend Yield (TTM)

CCCCN/A

XFORN/A

Rule of 40

CCCC-241.4

XFOR-611.6

EV/GP/RG

CCCCN/A

XFORN/A

Ticker research

View CCCC research View XFOR research

Metric	CCCC C4 Therapeutics, Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$349M	$274M
Enterprise Value	$271M	$156M
Price	$3.16	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	17.32x
EV/Sales	7.73x	9.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	28.09x
Revenue & Growth
Revenue (TTM)	$35M	$16M
Revenue Growth (YoY)	2.3%	-51.6%
Forward Rev Growth	-15.9%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	-544.2%
Net Margin (TTM)	-289.4%	-568.8%
FCF Margin (TTM)	-243.7%	-560.0%
Net Income (TTM)	$-101M	$-90M
FCF (TTM)	$-85M	$-89M
EPS (TTM)	-$0.78	-$0.71
ROE (TTM)	-4545.0%	-6305.0%
ROA (TTM)	-3090.0%	-3689.0%
ROIC (TTM)	-4545.0%	-4109.0%
Financial Health
Cash	$79M	$195M
Debt	$0	$77M
Net Cash/Debt	$79M	$118M
Current Ratio (TTM)	5.45x	11.30x
Quick Ratio (TTM)	5.29x	10.87x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	0.50
52W Performance	41.7%	-12.3%
YTD Performance	63.7%	-25.2%
% from 52W High	-38.9%	-39.8%
% from 52W Low	87.0%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.06x
FCF Yield (TTM)	-24.4%	-32.3%
Earnings Yield (TTM)	-29.0%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View XFOR research

Valuation

P/S Ratio

CCCC

9.97x

XFOR

17.32x

EV/FCF

CCCC

-3.17x

XFOR

-1.76x

Growth & revenue

Revenue Growth TTM

CCCC

2.3%

XFOR

-51.6%

Forward Revenue Growth

CCCC

-15.9%

XFOR

-27.7%

Profitability & performance

Gross Margin

XFOR

81.5%

CCCC

0.0%

ROE

CCCC

-4545.0%

XFOR

-6305.0%

FCF Yield %

CCCC

-24.4%

XFOR

-32.3%

52-Week Performance

CCCC

41.7%

XFOR

-12.3%

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

CCCC$349M

XFOR$274M

Enterprise Value

CCCC$271M

XFOR$156M

Price

CCCC$3.16

XFOR$2.91

P/E Ratio

CCCCN/A

XFORN/A

P/S Ratio

CCCC9.97x

XFOR17.32x

EV/Sales

CCCC7.73x

XFOR9.85x

EV/EBITDA

CCCC0.00x

XFOR0.00x

P/B Ratio

CCCC1.47x

XFOR1.81x

P/FCF Ratio

CCCCN/A

XFORN/A

EV/FCF

CCCC-3.17x

XFOR-1.76x

PEG Ratio

CCCCN/A

XFORN/A

Forward P/E (NTM)

CCCCN/A

XFORN/A

Forward P/S (NTM)

CCCC15.01x

XFOR28.09x

Revenue (TTM)

CCCC$35M

XFOR$16M

Revenue Growth (YoY)

CCCC2.3%

XFOR-51.6%

Forward Rev Growth

CCCC-15.9%

XFOR-27.7%

Gross Margin (TTM)

CCCC0.0%

XFOR81.5%

Operating Margin (TTM)

CCCC0.0%

XFOR0.0%

EBITDA Margin (TTM)

CCCC-283.8%

XFOR-544.2%

Net Margin (TTM)

CCCC-289.4%

XFOR-568.8%

FCF Margin (TTM)

CCCC-243.7%

XFOR-560.0%

Net Income (TTM)

CCCC$-101M

XFOR$-90M

FCF (TTM)

CCCC$-85M

XFOR$-89M

EPS (TTM)

CCCC-$0.78

XFOR-$0.71

ROE (TTM)

CCCC-4545.0%

XFOR-6305.0%

ROA (TTM)

CCCC-3090.0%

XFOR-3689.0%

ROIC (TTM)

CCCC-4545.0%

XFOR-4109.0%

Cash

CCCC$79M

XFOR$195M

Debt

CCCC$0

XFOR$77M

Net Cash/Debt

CCCC$79M

XFOR$118M

Current Ratio (TTM)

CCCC5.45x

XFOR11.30x

Quick Ratio (TTM)

CCCC5.29x

XFOR10.87x

Debt/Equity (TTM)

CCCC0.00x

XFOR0.49x

Debt/Assets (TTM)

CCCC0.0%

XFOR0.0%

Interest Coverage (TTM)

CCCCN/A

XFORN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

XFOR0.00x

Beta

CCCC3.16

XFOR0.50

52W Performance

CCCC41.7%

XFOR-12.3%

YTD Performance

CCCC63.7%

XFOR-25.2%

% from 52W High

CCCC-38.9%

XFOR-39.8%

% from 52W Low

CCCC87.0%

XFOR7.8%

Asset Turnover (TTM)

CCCC0.11x

XFOR0.06x

FCF Yield (TTM)

CCCC-24.4%

XFOR-32.3%

Earnings Yield (TTM)

CCCC-29.0%

XFOR-32.8%

Dividend Yield (TTM)

CCCCN/A

XFORN/A

Rule of 40

CCCC-241.4

XFOR-611.6

EV/GP/RG

CCCCN/A

XFORN/A

Ticker research

View CCCC research View XFOR research

Metric	CCCC C4 Therapeutics, Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$349M	$274M
Enterprise Value	$271M	$156M
Price	$3.16	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	17.32x
EV/Sales	7.73x	9.85x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	28.09x
Revenue & Growth
Revenue (TTM)	$35M	$16M
Revenue Growth (YoY)	2.3%	-51.6%
Forward Rev Growth	-15.9%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	-544.2%
Net Margin (TTM)	-289.4%	-568.8%
FCF Margin (TTM)	-243.7%	-560.0%
Net Income (TTM)	$-101M	$-90M
FCF (TTM)	$-85M	$-89M
EPS (TTM)	-$0.78	-$0.71
ROE (TTM)	-4545.0%	-6305.0%
ROA (TTM)	-3090.0%	-3689.0%
ROIC (TTM)	-4545.0%	-4109.0%
Financial Health
Cash	$79M	$195M
Debt	$0	$77M
Net Cash/Debt	$79M	$118M
Current Ratio (TTM)	5.45x	11.30x
Quick Ratio (TTM)	5.29x	10.87x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	0.50
52W Performance	41.7%	-12.3%
YTD Performance	63.7%	-25.2%
% from 52W High	-38.9%	-39.8%
% from 52W Low	87.0%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.06x
FCF Yield (TTM)	-24.4%	-32.3%
Earnings Yield (TTM)	-29.0%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View XFOR research